Akero Therapeutics
Compare Akero Therapeutics…Efruxifermin (FGF21 analog) for MASH. Novo Nordisk agreed to acquire Akero for $5.2B in late 2025, positioning MASH as combinable with GLP-1.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Akero TherapeuticsEfruxifermin (FGF21 analog) for MASH. Novo Nordisk agreed to acquire Akero for $5.2B in late 2025, positioning MASH as combinable with GLP-1.
Quarterly breakdown of revenue into costs and profit
Q4 2017 — Q3 2025
How revenue flows through costs to become profit
Assets = Liabilities + Equity
Q4 2017 — Q3 2025(All available data)
Cash position and cash generation
Q4 2017 — Q3 2025(All available data)